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Differential Impact of Serial Measurement of Nonplatelet
Thromboxane Generation on Long-Term Outcome After Cardiac
Surgery
Nikolaos Kakouros, MBBS, PhD; Tyler J. Gluckman, MD; John V. Conte, MD; Thomas S. Kickler, MD; Katherine Laws, RN;
Bruce A. Barton, PhD; Jeffrey J. Rade, MD
Background-—Systemic thromboxane generation, not suppressible by standard aspirin therapy and likely arising from nonplatelet
sources, increases the risk of atherothrombosis and death in patients with cardiovascular disease. In the RIGOR (Reduction in Graft
Occlusion Rates) study, greater nonplatelet thromboxane generation occurred early compared with late after coronary artery
bypass graft surgery, although only the latter correlated with graft failure. We hypothesize that a similar differential association
exists between nonplatelet thromboxane generation and long-term clinical outcome.
Methods and Results-—Five-year outcome data were analyzed for 290 RIGOR subjects taking aspirin with suppressed platelet
thromboxane generation. Multivariable modeling was performed to deﬁne the relative predictive value of the urine thromboxane
metabolite, 11-dehydrothromboxane B2 (11-dhTXB2), measured 3 days versus 6 months after surgery on the composite end point
of death, myocardial infarction, revascularization or stroke, and death alone. 11-dhTXB2 measured 3 days after surgery did not
independently predict outcome, whereas 11-dhTXB2 >450 pg/mg creatinine measured 6 months after surgery predicted the
composite end point (adjusted hazard ratio, 1.79; P=0.02) and death (adjusted hazard ratio, 2.90; P=0.01) at 5 years compared
with lower values. Additional modeling revealed 11-dhTXB2 measured early after surgery associated with several markers of
inﬂammation, in contrast to 11-dhTXB2 measured 6 months later, which highly associated with oxidative stress.
Conclusions-—Long-term nonplatelet thromboxane generation after coronary artery bypass graft surgery is a novel risk factor for
5-year adverse outcome, including death. In contrast, nonplatelet thromboxane generation in the early postoperative period
appears to be driven predominantly by inﬂammation and did not independently predict long-term clinical outcome. ( J Am Heart
Assoc. 2017;6:e007486. DOI: 10.1161/JAHA.117.007486.)
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T hromboxane A2 (TXA2) is a signal-activated eicosanoidgenerated from the metabolism of arachidonic acid via
the actions of cyclooxygenase (COX) and downstream
thromboxane synthase enzymes.1 In healthy adults, TXA2 is
produced predominantly by platelets in response to physio-
logic agonists, where it potentiates the activation of the
platelet in which it is formed. TXA2 is also released, causing
local ampliﬁcation of thrombotic stimuli by directly activating
adjacent platelets and vasoconstriction via binding to cellular
thromboxane-prostanoid receptors.2 The cardioprotective
effect of aspirin is principally mediated by the irreversible
inhibition of the platelet COX-1 enzyme, which suppresses
platelet TXA2 generation and platelet activation.
3
A substantial percentage of patients with cardiovascular
disease continue to generate signiﬁcant amounts of TXA2
despite aspirin therapy, which places them at risk for adverse
cardiovascular events.4–8 Although initially thought to repre-
sent a failure of aspirin to inhibit platelet TXA2 generation,
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emerging evidence suggests that residual TXA2 generation
derives principally from nonplatelet sources not suppressible
by once-daily dosing regimens.6,9–13
In the RIGOR (Reduction in Graft Occlusion Rates) study,
nonplatelet TXA2 generation was identiﬁed as a novel risk
factor for saphenous vein graft thrombotic occlusion after
ﬁrst-time coronary artery bypass graft (CABG) surgery.6 Little
is known about how extreme physiologic stress affects
nonplatelet TXA2 generation, how it changes over time in a
given patient, or how predictive it is of clinical outcome when
measured in acute versus chronic conditions. To address
these questions, we compared nonplatelet TXA2 generation in
the RIGOR study population measured 3 days after surgery
with that measured 6 months later and determined how
predictive each was of 5-year outcome. To gain insight into
possible sources of nonplatelet TXA2 generation, we also
investigated if variables associated with nonplatelet TXA2
generation in the early postoperative period differed from
those after a return to long-term baseline state.
Methods
Patient Population
The RIGOR study was a multicenter observational study of
368 subjects undergoing ﬁrst-time CABG surgery between
October, 2003 and October, 2006, designed to investigate the
association between thrombotic risk factors and early saphe-
nous vein graft occlusion. Detailed descriptions of the study
design, patient characteristics, and principal ﬁndings have
previously been published.6,14,15 Institutional review board
approval was obtained at each participating site, and written
consent was obtained from all subjects. Any patient
≥18 years old undergoing ﬁrst-time CABG surgery with
implantation of at least 1 saphenous vein graft was eligible
for enrollment. Those with an anticipated requirement for
postoperative oral anticoagulation or antiplatelet therapy
other than aspirin were excluded, although subjects given
these agents for unforeseen postoperative conditions (eg,
atrial ﬁbrillation) continued in the study. All patients were
administered aspirin (300–325 mg) within 24 hours of
surgery. At hospital discharge, patients were given a supply
of 325-mg enteric-coated aspirin and instructed to take 1
tablet daily for 6 months, unless directed otherwise by their
physician. Pill counts were performed at each postoperative
encounter. Demographic, historical, procedural, clinical, and
laboratory data were recorded for all patients. Subjects were
contacted yearly around the surgical anniversary date for up
to 5 years unless known to have expired. Intercurrent clinical
end points were veriﬁed by review of medical records, and
deaths were conﬁrmed by medical and/or Social Security
death records.
Laboratory Studies
Details of the laboratory methods used have been described
previously.16 Platelet function studies could only be per-
formed 3 days after CABG surgery in subjects enrolled at the
Johns Hopkins Hospital (Baltimore, MD) but were performed in
all subjects 6 months after surgery, at the time of graft
patency assessment. Platelet-rich plasma was prepared from
citrated blood, and the platelet count was adjusted to
180 000/mm3 by the addition of platelet-poor plasma.
Undiluted samples with a platelet count of <100 000/mm3
were excluded from analysis. Impedance platelet aggregom-
etry was performed on platelet-rich plasma by stimulation
with a panel of agonists, including 0.5 mmol/L arachidonic
acid, using an aggregometer, and the maximum aggregation
response within 5 minutes was recorded (in ohms). Platelet
COX-1 activity and TXA2 generation were considered to be
fully suppressed by aspirin if arachidonic acid–induced
platelet aggregation was ≤1 O (normal range in our laboratory
for aspirin-na€ıve subjects, 5–17 O) on the basis of data
demonstrating that suppression of platelet TXA2 generation
>99% is required to suppress arachidonic acid–induced
platelet aggregation by 95%.17 Systemic TXA2 generation
was quantiﬁed by measuring the concentration of its stable
metabolite, 11-dehydrothromboxane B2 (11-dhTXB2), in urine
Clinical Perspective
What Is New?
• Despite being greater in magnitude, nonplatelet thrombox-
ane generation occurring immediately after cardiac surgery
does not have the same long-term prognostic value as that
occurring following recovery and return to a baseline state.
• Inﬂammation appears to be a major stimulus for nonplatelet
thromboxane generation in the immediate postoperative
state, whereas oxidative stress is the predominant stimulus
in the long-term baseline state.
• These ﬁndings suggest that the source, and not necessarily
only the overall magnitude, of nonplatelet thromboxane
generation is an important determinant of its impact on
cardiovascular risk.
What Are the Clinical Implications?
• Although nonplatelet thromboxane generation is emerging
as a novel cardiovascular risk factor, the context in which it
is assessed is important for its prognostic signiﬁcance.
• Identifying the sources of nonplatelet thromboxane gener-
ation will facilitate a better understanding of the pathobi-
ological characteristics of nonplatelet thromboxane
generation and aid in the development of therapies to
mollify its effects.
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by ELISA and expressed as pg/mg of urine creatinine
(coefﬁcients of variance, ≤10%; lower limit of detection,
25 pg/mL).
Assessment of Graft Patency and Left Ventricular
Ejection Fraction
The patency of venous and arterial grafts was assessed
6 months after CABG surgery by computed tomographic
angiography, as previously described.14,15 Data from clini-
cally driven invasive coronary angiograms could be used for
the primary end point analysis if performed within 6 weeks
of the anticipated 6-month follow-up visit or if it was the
only assessment of graft patency before a clinical end point.
Multisegmented grafts were statistically considered as
separate grafts, according to the Society of Thoracic
Surgeons criteria. Two blinded reviewers analyzed recon-
structed 3-dimensional images to classify grafts as patent
(containing stenoses of 0%–75%), signiﬁcantly diseased
(containing stenoses of 76%–99%), or occluded (containing
a 100% stenosis). In cases of discordance, a third reviewer
adjudicated all grafts in that patient. Left ventricular
ejection fractions were calculated from reconstructed com-
puted tomographic angiography images using computer
software.
Statistical Analysis
Data from patients who survived the index hospitalization and
underwent graft patency assessment were included in the
present analysis. Baseline characteristics are presented as
meanSD or median (interquartile range) for continuous
variables and as proportions for categorical variables. Pro-
portions were compared using a Fisher exact test, and
continuous variables were compared by Student t test or
Wilcoxon rank-sum test, as appropriate. For graft patency
analysis, the small proportion of grafts classiﬁed as severely
diseased was considered as occluded. Nonnormally dis-
tributed variables were transformed using natural log or
negative inverse square, as indicated. Median, upper quartile,
or upper tertile splits were used to categorize continuous
variables that could not be normalized, as indicated. Differ-
ences were considered signiﬁcant when P<0.05. A propor-
tional hazard Cox survival model was used to evaluate the
independent determinants of the predeﬁned composite
outcome of death, myocardial infarction, revascularization
(both surgical and percutaneous), and stroke, as well as death
alone (because it was a major determinant of the composite
outcome). The time origins for the survival analyses were set
at the time of surgery and the time of graft patency
assessment when urine 11-dhTXB2 was measured 6 months
after surgery. For analyses involving the latter, events
occurring before the 6-month landmark were excluded. Cox
modeling was performed using clustering by patient; for the
composite end point, stratiﬁcation by individual end point was
used. Kaplan-Meier survival plots comparing various predic-
tors were constructed. Predictors with unadjusted P≤0.15
were included in the initial multivariable Cox model. The
explained relative risk by the models was assessed using the
Royston modiﬁed version of the Nagelkerke R2, including a
bootstrap conﬁdence interval.18 Backward stepwise modeling
with bootstrapping was performed, and predictors appearing
in >50% of resulting models were considered in the ﬁnal
model, with selection guided by the Bayesian information
criterion and R2. Multivariable fractional polynomial interac-
tion analysis was used to assess for interactions between
covariates. The assumption of proportionality was evaluated
by introducing natural log-time–dependent covariates for
predictors in the Cox model and testing for signiﬁcance.
The ﬁnal optimized multivariable Cox proportional hazard
models were used to derive adjusted hazard ratios. Robust
univariate regression was performed for predictors of 11-
dhTXB2 using variables deemed biologically plausible or
supported by the literature. Highly collinear covariates were
identiﬁed using the Fisher exact test and Pearson correlation
for categorical and continuous variables, respectively, and
were eliminated on the basis of clinical signiﬁcance. Variables
with P≤0.15 on the initial univariate analysis were included in
the initial multivariate model. The Furnival-Wilson leaps-and-
bounds algorithm was used for variable subset selection, and
the model was optimized on the basis of the Akaike
information criteria. The coefﬁcient estimates are reported
standardized to a variance of 1 (b coefﬁcients), to facilitate
comparison of the predicted magnitude of change in the
dependent variable per unit change in the predictor. The
relative importance of each variable in the multivariable model
was assessed by dominance analysis.13,19 Analyses were
performed using Stata 13.0 for Windows.
Results
Study Population Characteristics
Of the 368 subjects enrolled in the RIGOR study at the 4
participating sites, 293 survived the index hospitalization,
were receiving long-term aspirin therapy, and had measure-
ment of both urine 11-dhTXB2 and arachidonic acid–induced
platelet aggregation at the time of graft patency assessment
at 6 months (median, 189 days; interquartile range, 182–
202 days) after CABG surgery. Because 3 subjects were
excluded from analysis because of persistent arachidonic
acid–induced platelet aggregation, despite aspirin therapy at
this time point, 290 subjects formed the study cohort. Of
these subjects, 271 also had measurement of urine 11-
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dhTXB2 a median of 3 days (interquartile range, 3–4 days)
after CABG surgery. Only 198 subjects also had veriﬁed
suppression of arachidonic acid–induced platelet aggregation
at this time point, given that platelet function testing was only
available at only 1 enrolling site. The median duration of
clinical follow-up in the study cohort was 1828 days
(interquartile range, 1482–1846 days) after surgery. The
characteristics of the study cohort as a whole and in subjects
Table 1. Baseline, Operative, and Postoperative Characteristics of Subjects Stratiﬁed by 11-dhTXB2 Measured at 3 Days and
6 Months After CABG Surgery
Characteristic Cohort (n=288)
3 Days 6 Months
<891 pg/mg
Creatinine
(n=214)
≥891 pg/mg
Creatinine
(n=74) P Value
<450 pg/mg
Creatinine
(n=212)
≥450 pg/mg
Creatinine
(n=76) P Value
Age, meanSD, y 63.310.0 62.810.1 64.89.9 0.12 62.49.7 65.910.7 0.01
Male sex 229 (80) 175 (82) 39 (18) 0.13 178 (84) 51 (67) 0.003
White race 250 (87) 187 (87) 63 (85) 0.69 192 (91) 58 (76) 0.003
Body mass index, median (interquartile range), kg/m2 30 (26–33) 29 (26–33) 28 (25–33) 0.55 30 (26–33) 29 (25–33) 0.21
Medical history
Hypertension 236 (82) 173 (81) 63 (85) 0.49 174 (83) 62 (82) 0.86
Dyslipidemia 241 (84) 178 (84) 63 (85) 0.86 177 (84) 64 (84) 1.0
Diabetes mellitus 99 (35) 68 (32) 31 (42) 0.12 63 (30) 36 (48) 0.007
Heart failure 35 (12) 18 (8) 17 (23) 0.002 20 (9) 15 (20) 0.024
Peripheral/cerebral-vascular disease 50 (17) 31 (14) 19 (26) 0.03 33 (16) 17 (22) 0.216
Atrial fibrillation 10 (3) 5 (2) 5 (7) 0.13 6 (3) 4 (5) 0.30
Tobacco use at surgery 68 (24) 42 (20) 26 (35) 0.01 45 (21) 23 (30) 0.12
Myocardial infarction 118 (41) 78 (36) 40 (54) 0.009 81 (38) 37 (49) 0.14
Prior PCI 59 (20) 40 (19) 19 (26) 0.24 45 (21) 14 (18) 0.74
Preoperative LVEF, % 0.004 0.61
≤30 24 (8) 11 (5) 13 (18) 16 (8) 8 (11)
30–50 97 (34) 75 (35) 22 (30) 70 (33) 27 (36)
>50 167 (58) 128 (60) 39 (53) 126 (59) 41 (54)
Urgent/emergent surgery 178 (62) 120 (56) 58 (78) 0.001 128 (60) 50 (66) 0.41
EuroScore, median (interquartile range) 4 (2–5) 3 (2–5) 4 (2–7) 0.01 3 (1–5) 5 (3–6) 0.005
Arterial graft implanted 280 (97) 208 (97) 72 (97) 0.96 206 (97) 74 (97) 0.93
No. of SVGs per subject 0.64 0.25
1 78 (27) 55 (26) 23 (31) 57 (27) 21 (28)
2 121 (42) 90 (42) 31 (42) 85 (40) 36 (47)
≥3 89 (31) 69 (32) 20 (27) 70 (33) 19 (25)
Medications at urine 11-dhTXB2 measurement
Aspirin 288 (100) 214 (100) 74 (100) 1.0 212 (100) 76 (100) 1.0
Dose, <325 mg/d 30 (10) 0 (0) 0 (0) 1.0 17 (8) 13 (17) 0.046
Nonaspirin antiplatelet agent 32 (11) 27 (13) 10 (14) 0.84 20 (9) 12 (16) 0.14
Oral anticoagulation 14 (5) 17 (8) 17 (23) 0.001 7 (3) 7 (9) 0.06
b Blocker 240 (83) 210 (98) 74 (100) 0.58 181 (85) 59 (78) 0.15
ACE inhibitor/ARB 178 (62) 107 (50) 42 (57) 0.35 133 (63) 45 (59) 0.59
Lipid-lowering agent 255 (89) 207 (97) 74 (100) 0.48 192 (91) 63 (83) 0.09
Data are given as number (percentage) unless otherwise indicated. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft;
11-dhTXB2, 11-dehydrothromboxane B2; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; and SVG, saphenous vein graft.
All statistcally signiﬁcant P values were in bold.
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stratiﬁed by urine 11-dhTXB2 values of 891 pg/mg creatinine,
measured 3 days after surgery (upper-tertile threshold), and
450 pg/mg creatinine, measured 6 months after surgery
(upper-quartile threshold previously shown to independently
correlate with vein graft thrombotic occlusion6), are shown in
Table 1. Similar to other studies, older age, female sex, and
nonwhite race were demographic characteristics associated
with higher 11-dhTXB2 levels when measured 6 months after
surgery.5,20 In contrast, no demographic characteristics were
associated with higher 11-dhTXB2 levels when measured
3 days after surgery.
Median 11-dhTXB2 in the study cohort was signiﬁcantly
higher 3 days (648 pg/mg creatinine; interquartile range,
398–1171 pg/mg creatinine) compared with 6 months after
surgery (331 pg/mg creatinine; interquartile range, 232–
462 pg/mg creatinine; P<0.0001) (Figure 1A). In the 198
subjects with paired samples and veriﬁed suppression of
platelet thromboxane generation, the change in urine 11-
dhTXB2 over time was linearly related with 151 subjects (76%)
manifesting a net decrease in 11-dhTXB2 after 6 months
(median change, 323 pg/mg creatinine; interquartile range,
173–668 pg/mg creatinine) and only 48 subjects (24%)
manifesting a net increase (median change, 119 pg/mg
creatinine; interquartile range, 48–201 pg/mg creatinine)
(Figure 1B).
Urine 11-dhTXB2 as a Predictor of Outcome
Univariate analyses were used to explore the association of
urine 11-dhTXB2, along with a wide array of demographic,
clinical, and laboratory variables, to the primary composite
outcome of death, myocardial infarction, revascularization, or
stroke at 6 months (Table S1) and both the composite
outcome and death alone at 5 years (Table S2). Urine 11-
dhTXB2, measured 3 days after surgery and expressed as a
dichotomous (using the upper-tertile threshold of 891 pg/mg
creatinine) but not as a continuous variable, was signiﬁcantly
associated with the composite outcome end point at
6 months. Urine 11-dhTXB2 measurements at both 3 days
and 6 months were signiﬁcantly associated with the 5-year
composite outcome end point and death, a major determinant
of the composite end point (Figure 2). Interestingly, there was
no association with revascularization, the other major driver
of the composite end point (Table S3). To determine the
relative predictive value of 11-dhTXB2 measured at both time
points, multivariable models were constructed to identify
independent predictors of outcome. Urine 11-dhTXB2 mea-
sured 3 days after CABG surgery was not an independent
predictor of the composite outcome at 6 months (Table S4) or
at 5 years (Table 2). In contrast, urine 11-dhTXB2 measured
6 months after surgery was an independent predictor of both
the composite outcome and death at 5 years (Table 2).
Occlusion of left internal mammary grafts, but not vein grafts,
6 months after CABG surgery predicted the composite end
point, which was predominantly driven by revascularization.
Not unexpectedly, concurrent peripheral or cerebrovascular
disease, postoperative renal insufﬁciency, and reduced ejec-
tion fraction independently predicted higher long-term mor-
tality; statin therapy predicted lower long-term mortality.
Variables Associated With Nonplatelet TXA2
Generation Early After Surgery
In a prior analysis of this study cohort,13 oxidative stress, as
measured by urine 8-iso-prostaglandin 2a, was identiﬁed as
the strongest variable associated with urine 11-dhTXB2,
measured 6 months after surgery, accounting for approxi-
mately half of the modeled effect and consistent with data
from other study populations.20,21 Age, race, statin use, and
aspirin dose were also associated, but to lesser degrees.
Given the observed differences in subject characteristics
associated with high 11-dhTXB2 levels when measured at
Figure 1. A, Distribution of urine 11-dehydrothromboxane B2
(11-dhTXB2) 3 days and 6 months after coronary artery bypass
graft (CABG) surgery. B, Change in urine 11-dhTXB2 from 3 days
to 6 months after CABG surgery in individual subjects.
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different time points (Table 1), we sought to understand if
stimuli for nonplatelet TXA2 generation during the early
perioperative period, when subjects were under acute phys-
iologic stress, differed from those 6 months later, when
subjects would more likely to be at their physiologic baseline.
Modeling of variables associated with 11-dhTXB2 measured
3 days after surgery revealed that red cell distribution width, a
novel marker of inﬂammation and cardiovascular risk,22–25
was the strongest associated variable, accounting for nearly a
third of the modeled effect (Table 3). Other markers and
modulators of inﬂammation, such as C-reactive protein and
statin use, were also associated to lesser degrees, as was
oxidative stress, as measured by urine 8-iso-prostaglandin2a.
Discussion
The major ﬁndings of this study were as follows: (1) in patients
undergoing CABG surgery, nonplatelet TXA2 generation is
markedly higher in the early postoperative period than 6 months
later; (2) nonplatelet TXA2 generation measured 6 months after
CABG surgery, but not that measured in the early postoperative
period, independently predicted long-term outcome, particularly
mortality; and (3) althoughoxidative stress is amajor stimulus for
nonplatelet TXA2 generation 6 months after CABG surgery,
inﬂammation is a stronger stimulus for nonplatelet TXA2
generation in the early postoperative period.
Studies have emerged in recent years demonstrating that
persistent TXA2 generation in patients with cardiovascular
disease undergoing aspirin therapy predicts an increased risk
of atherothrombosis and death.4,7,8 Although initially assumed
to be attributable to the failure of aspirin to inhibit platelet
COX-1–mediated thromboxane generation and consequent
platelet activation, it is now recognized that aspirin is efﬁcient
at inhibiting platelet COX-1 and that much of the residual
TXA2 generation in patients taking aspirin originates from
nonplatelet sources.26–28 A unique feature of our analysis was
that it only included subjects in whom inhibition of platelet
thromboxane generation was veriﬁed, conclusively demon-
strating that TXA2 originating from nonplatelet tissue
adversely affects clinical outcome and survival.
Figure 2. Kaplan-Meier plots for: survival free of myocardial infarction, revascularization, or stroke (A) and survival alone (B) in subjects
stratiﬁed by urine 11-dehydrothromboxane B2 (11-dhTXB2) ≤891 (red) or >891 (blue) pg/mg creatinine measured 3 days after coronary artery
bypass graft (CABG) surgery; survival free of myocardial infarction, revascularization, or stroke (C) and survival alone (D) in subjects stratiﬁed by
urine 11-dhTXB2 ≤450 (red) or >450 (blue) pg/mg creatinine measured 6 months after CABG surgery (landmark). CI indicates conﬁdence
interval; and HR, hazard ratio.
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Sources of nonplatelet TXA2 generation have not been
conclusively identiﬁed and may conceivably vary depending
on the patient population and conditions under study. Many
tissues and cell types produce TXA2, which is quickly
degraded to TXB2, a relatively stable metabolite that circu-
lates widely. TXB2 itself is extensively metabolized via
enzyme-mediated b oxidation and dehydrogenation to dozens
of different stable end-order metabolites, including 11-
dhTXB2, that are concentrated in the urine.
29 Because TXB2
produced from TXA2 generated in the kidney does not
circulate and is, therefore, not subjected to extensive further
metabolism, urine levels of TXB2 are considered to predom-
inantly represent renal TXA2 generation; those of 11-dhTXB2
are considered to predominantly represent extrarenal sys-
temic TXA2 generation.
30 Measurement of urine 11-dhTXB2 in
our study was performed using an ELISA with high speciﬁcity
for this metabolite and strong correlation with values
measured by mass spectrometry.31 Two candidate sources
for signiﬁcant nonrenal, nonplatelet TXA2 generation in our
study population include vascular endothelial and inﬂamma-
tory cells based on convincing in vitro data showing that each
is capable of producing TXA2.
13,32–34
A second unique feature of our study that helps gain
insight into potential sources of nonplatelet TXA2 generation
was the serial measurement of urine 11-dhTXB2 in individual
subjects during 2 markedly different physiologic states: a
period of intense physiologic stress and inﬂammation induced
by cardiac surgery and then 6 months later when subjects
would have likely returned to their physiologic baseline. We
previously found that urine 11-dhTXB2 levels measured in
subjects 6 months after CABG surgery were strongly corre-
lated with evidence of increased oxidative stress and were
inﬂuenced by age, sex, and race, similar to other studies of
patients with stable cardiovascular disease or diabetes
Table 2. Multivariable Cox Proportional Hazard Models for 5-Year Outcomes
Variable
Death, Myocardial Infarction, Revascularization,
and Stroke Death
Adjusted HR 95% CI P Value Adjusted HR 95% CI P Value
Model 1*
Peripheral/cerebrovascular disease 2.47 1.42–4.32 0.001 3.34 1.52–7.32 0.003
Insulin therapy 2.31 1.31–4.08 0.004
Lipid-lowering agent 0.34 0.15–0.77 0.01
eGFR, mL/min per 1.73 m2 0.98 0.95–1.0 0.04
Urine 11-dhTXB2 at 6 mo (ln pg/mg creatinine) 1.59 1.0–2.54 0.05 2.36 1.24–4.50 0.009
LIMA occlusion 2.95 1.50–5.81 0.002
Postoperative LVEF, %
≤30 2.58 1.10–6.03 0.03 5.45 0.94–14.85 0.06
30–50 2.67 1.54–5.63 <0.001 3.67 1.50–8.14 0.004
>50 Reference Reference
Model 2†
Peripheral/cerebrovascular disease 2.50 1.41–4.42 0.002 3.58 1.63–7.89 0.002
Insulin therapy 2.21 1.22–3.98 0.009
Lipid-lowering agent 0.34 0.16–0.75 0.007
eGFR, mL/min per 1.73 m2 0.97 0.95–1.0 0.03
Urine 11-dhTXB2 at 6 mo (>450 pg/mg creatinine) 1.79 1.08–2.96 0.02 2.90 1.29–6.50 0.01
LIMA graft occlusion 3.20 1.62–6.34 0.001
Postoperative LVEF, %
≤30 2.80 1.14–6.90 0.025 3.51 0.71–17.33 0.12
30–50 2.66 1.53–4.62 0.001 3.43 1.53–7.67 0.003
>50 Reference Reference
CI indicates conﬁdence interval; 11-dhTXB2, 11-dehydrothromboxane B2; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; LIMA, left internal mammary artery; and LVEF, left
ventricular ejection fraction.
*For death, myocardial infarction, revascularization, and stroke: pseudo R2 0.47 (95% CI: 0.31–0.69). For death: pseudo R2 0.71 (95% CI: 0.49–0.93).
†For death, myocardial infarction, revascularization, and stroke: pseudo R2 0.47 (95% CI: 0.31–0.70). For death: pseudo R2 0.70 (95% CI: 0.49–0.92).
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mellitus receiving aspirin therapy.13,20,35 Our ﬁndings that
cultured endothelial cells under oxidative stress generate
TXA2 and have the enzymatic capacity to metabolize it to 11-
dhTXB2
13 provide evidence that dysfunctional vascular
endothelium may be a signiﬁcant source of in vivo nonplatelet
TXA2 generation.
13 In contrast, urine 11-dhTXB2 measured in
the early postoperative period was associated with multiple
markers of inﬂammation, but not with age, race, or sex. This
suggested that inﬂammatory cells, such as monocytes, that
produce TXA2 when activated
34,36,37 may be a signiﬁcant
source of in vivo nonplatelet TXA2 generation during condi-
tions of intense inﬂammation. The marked nonplatelet TXA2
generation that occurred during the immediate postoperative
period did not independently predict long-term outcome,
whereas the nonplatelet TXA2 generation that was produced
over a long time did independently predict long-term
outcome. This raises the possibility, analogous to that
observed with C-reactive protein, that the source of non-
platelet TXA2 generation, rather than its overall magnitude,
might be the more important determinant of its impact on
clinical outcome.
How nonplatelet TXA2 generation modiﬁes cardiovascular
risk and mortality is also unknown. The lack of relationship
between urine 11-dhTXB2 and platelet function in the RIGOR
study6,13 and the inability of dual antiplatelet therapy to alter
the associated hazard of 11-dhTXB2 to outcome in the
Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management and Avoidance (CHARISMA) study5
suggest that increased platelet reactivity is not the predomi-
nate mechanism by which nonplatelet TXA2 generation causes
atherothrombosis and death. We previously found that non-
platelet TXA2 generation is a novel risk factor for early vein graft
failure, which is predominantly attributable to thrombotic
occlusion.6,15,38 TXA2 has been shown to be capable of
stimulating expression of tissue factor and adhesion molecules
in endothelial cells, suggesting that alteration in endothelial
thromboresistance may be one mechanism by which it
mediates thrombosis.39–41 Nonplatelet TXA2 generation may
also promote the progression of atherosclerosis. This is
supported by studies in apolipoprotein E–deﬁcient mice that
revealed that atherogenesis was suppressed by deletion or
pharmacologic inhibition of the thromboxane-prostanoid recep-
tor but not by the administration of aspirin.42,43 Whether
nonplatelet TXA2 generation is a marker or mediator of
atherothrombosis in humans will need to be determined by
clinical trials aimed at reducing its production or blocking its
effects on the thromboxane-prostanoid receptor.
There are several limitations to the present study. Although
the RIGOR study cohort was extremely well phenotyped, thus
permitting exclusion of subjects with persistent platelet TXA2
generation, it was of moderate size and composed only of
subjects with established cardiovascular disease who, by
deﬁnition, had undergone surgical revascularization. The
impact of nonplatelet TXA2 generation on outcome in other
larger and nonselected study populations will need to be
determined. Because the cause of death could not be
ascertained for all expired subjects, the end point analysis
was performed for all-cause mortality, although most deaths
were known to be cardiovascular in origin. Although compli-
ance with aspirin therapy was veriﬁed during the 6-month
active phase of the study by pill counts, it could not be veriﬁed
during the 5-year follow-up phase of the study and was
dependent on subject self-reporting. Given that standard
aspirin therapy does not suppress nonplatelet TXA2 genera-
tion but is only critical for its identiﬁcation, the effects on
outcome of noncompliance during the follow-up period would
be expected to be distributed between groups and not likely
affect the results of the study. Finally, because platelet
function testing was only available at 1 of the enrolling sites,
not all subjects in whom urine 11-dhTXB2 was measured early
after surgery were included in the analysis. Thus, this could
have conceivably biased the results. However, additional
analyses (data not shown) with inclusion of these subjects,
95% of whom would be expected to have aspirin-induced
suppression of platelet thromboxane generation at this time
point,6 did not alter ﬁndings that nonplatelet thromboxane
generation measured in the early perioperative period does
not independently predict outcome.
In summary, nonplatelet TXA2 generation is a predictor of
early graft failure after CABG surgery and of long-term
outcome, including mortality. The source of nonplatelet TXA2
generation, which can vary in individual patients under
Table 3. Risk Factors for Urine 11-dhTXB2 (ln pg/mg
Creatinine) Measured Early After CABG Surgery After
Adjustment of Other Variables by Multivariable Regression
Analysis
Variable
Standardized
Coefﬁcient P Value
Dominance
Weight
Dominance
Ranking
RDW (%3) 0.34 <0.001 0.33 1
Heparin use
before surgery
0.26 <0.001 0.18 2
FFP transfusion
(<2 vs ≥2 U)
0.21 <0.001 0.17 3
Urine 8-iso-PGF2a
(ln pg/mg
creatinine)
0.19 0.002 0.17 4
C-reactive protein
(mg/L1/2)
0.15 0.017 0.08 5
Lipid-lowering
therapy
0.12 0.002 0.07 6
Pseudo R2 (95% conﬁdence interval), 0.45 (0.34–0.56). CABG indicates coronary artery
bypass graft; 11-dhTXB2, 11-dehydrothromboxane B2; FFP, fresh-frozen plasma; 8-iso-
PGF2a, 8-iso-prostaglandin 2a; and RDW, red cell distribution width.
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different physiologic conditions, may be a more important
determinant of outcome than its overall magnitude.
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Table S1. Univariate analyses of variables associated with 6-month composite endpoint (death, 
myocardial infarction, revascularization and stroke). 
 Composite endpoint 
 
Variable HR P-value 
Demographic/pre-operative variables   
Age (years) 1.0 0.98 
Male sex 2.01 0.18 
White race (vs. non-white race) 0.58 0.39 
Body mass index (kg/m2) 0.96 0.46 
Medical History of:   
     Hypertension 1.75 0.47 
     Dyslipidemia 1.54 0.51 
     Diabetes 1.32 0.58 
     Heart failure 1.71 0.32 
     Peripheral/cerebrovascular disease 0.95 0.92 
       Atrial fibrillation 6.47 0.001 
     Preoperative tobacco use 1.73 0.28 
     Myocardial infarction  1.02 0.97 
     Prior PCI 1.65 0.35 
Pre-operative LVEF   
     ≤30% 1.35 0.66 
     30-50% 0.88 0.81 
     >50% Reference  
   
Surgical variables   
Urgent/Emergent surgery 1.64 0.31 
Euroscore 1.05 0.48 
Arterial graft implanted 0.86 0.88 
Number of SVG per subject   
     1 Reference  
     2 0.22 0.01 
     ≥3 0.54 0.35 
CABG only (vs concurrent valve surgery) 0.38 0.04 
Cardiopulmonary bypass time (ln min) 2.15 0.21 
Cross clamp 1.0 1.0 
Cross clamp time (ln min) 1.2 0.75 
Heparin units (ln units) 0.61 0.49 
Protamine dose (mg2) 1.0 0.86 
Crystalloid dose (mL1/2 ) 1.03 0.05 
Colloid dose (mL) 1.0 0.55 
Packed RBC transfusion 1.70 0.25 
Packed RBC units –  None Reference  
                                  1-2 1.66 0.34 
                                  >3 1.73 0.27 
Cell saver volume (ml1/2) 1.0 0.90 
FFP transfusion 1.15 0.74 
FFP units: None Reference  
                  1-2 4.96 0.12 
                   >2 17.4 0.008 
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Platelet transfusion 1.80 0.12 
Platelet units -None Reference  
                       1-2 1.55 0.34 
                        >3 2.21 0.10 
Post-operative variables   
Medications:   
     Non-aspirin antiplatelet 2.89 0.08 
     Oral anticoagulation 2.51 0.38 
     Beta-blocker 0.29 0.05 
     ACE Inhibitor/ARB 1.35 0.54 
      Insulin 0.64 0.63 
      Insulin sensitizer 1.30 0.68 
      Insulin secretagogue 1.68 0.37 
eGFR (mL/min/1.73m2) 1.0 0.27 
Leukocyte count (103/mm3) 0.96 0.64 
Hematocrit (%) 0.96 0.40 
Red cell distribution width (≤14.5 vs >14.5%) 1.46 0.43 
Platelet count (<150 vs. ≥150x 103/mm3) 1.16 0.75 
Reticulocyte (ln %) 0.67 0.55 
Blood Group: O vs. other 0.58 0.28 
C-reactive protein (mg/L1/2) 0.96 0.67 
Fibrinogen (<390 vs. ≥390 mg/dL) 1.08 0.91 
vonWillebrand factor ( >150 vs. ≤150%) 4.22 0.16 
Urine 8-isoPGF2α (ln pg/mg creatinine) 1.72 0.15 
Urine 8-isoPGF2α (<1870 vs. ≥1870 pg/mg creatinine) 1.32 0.61 
Urine 11-dhTXB2  (ln pg/mg creatinine) 1.72 0.08 
Urine 11-dhTXB2 tertiles   
         ≤ 487 pg/mg creatinine Reference  
         >487 to ≤891pg/mg creatinine 1.98 0.25 
         > 891 pg/mg creatinine 3.56 0.03 
Impedance platelet aggregometry (ohms)   
       ADP (20μM) 0.90 0.11 
       ADP (10μM) 0.87 0.03 
       ADP (5μM) 0.90 0.06 
       Collagen (1 µg/mL) 0.99 0.74 
       Epinephrine (50 µM) 0.98 0.67 
PFA-100 Collagen-ADP (Closure Time in sec-1) 1.01 0.01 
PFA-100 Collagen-ADP (Closure Time ≤88 sec vs. >88 sec) 0.27 0.03 
PFA-100 Collagen-Epinephrine (Closure Time in sec-1) 0.90 0.11 
Abbreviations: PCI= percutaneous coronary intervention; LVEF= left ventricular ejection fraction; SVG= 
saphenous vein graft; RBS= red blood cell; FFP= fresh-frozen plasma; ACE= angiotensin converting 
enzyme; ARB= angiotensin receptor blocker; 11-dhTXB2= 11-dehydro thromboxane B2; eGFR= 
estimated glomerular filtration rate; ADP= adenosine diphosphate; PFA-100= Platelet Function Analyzer-
100 
 
 
 
 
 by guest on D
ecem
ber 7, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
 
 
Table S2. Univariate analyses of variables associated with 5-year composite endpoint (death, 
myocardial infarction, revascularization and stroke) and mortality. 
 Composite endpoint 
 
Death 
Variable HR P-value HR P-value 
Demographic/pre-operative variables     
Age (years) 0.99 0.63 1.04 0.07 
Male sex 2.07 0.015 1.60 0.29 
White race (vs. non-white race) 0.48 0.034 0.39 0.046 
Body mass index (kg/m2) 0.99 0.75 0.98 0.63 
Medical History of:     
     Hypertension 1.43 0.38 1.50 0.51 
     Dyslipidemia 1.29 0.49 1.01 0.98 
     Diabetes 2.34 0.002 2.30 0.04 
     Heart failure 2.38 0.013 2.84 0.02 
     Peripheral/cerebrovascular disease 3.94 <0.001 4.11 0.001 
       Atrial fibrillation 1.77  0.32 2.33 0.25 
     Preoperative tobacco use 1.70 0.08 2.42 0.03 
     Myocardial infarction  1.26 0.40 0.99 0.98 
     Prior PCI 0.83 0.59 0.17 0.08 
Pre-operative LVEF     
     >50% Reference  Reference  
     30-50% 1.40 0.25 1.31 0.55 
     ≤30% 1.63 0.39 2.38 0.13 
     
Surgical variables     
Urgent/Emergent surgery 1.1 0.84 0.87 0.73 
Euroscore 1.12 0.02 1.18 0.005 
Arterial graft implanted 1.93 0.51 0.81 0.84 
Number of SVG per subject     
     1 Reference  Reference  
     2 1.31 0.42 0.98 0.95 
     3 0.63 0.29 0.40 0.17 
     ≥4 0.52 0.28 1.0 1.0 
CABG only (vs concurrent valve surgery) 0.52 0.11 0.27 0.01 
Cardiopulmonary bypass time (ln min) 2.97 0.003 4.78 0.005 
Cross clamp 0.48 0.16 0.84 0.87 
Cross clamp time (ln min) 2.0 0.08 2.44 0.16 
Heparin units (ln units) 0.37 0.01 0.14 0.003 
Protamine dose (mg1/2) 1.0 0.14 1.0 0.62 
Crystalloid dose (mL1/2 ) 1.0 0.38 1.0 0.56 
Colloid dose (mL) 1.0 0.73 1.0 0.85 
Packed RBC transfusion 3.5 <0.001 4.78 0.01 
Packed RBC units :  None Reference  Reference  
                                  1-2 2.70 0.012 3.38 0.08 
                                  >3 4.16 <0.001 5.94 0.005 
Cell saver volume (mL1/2) 1.04 0.003 1.06 0.02 
FFP transfusion 2.18 0.003 3.18 0.005 
FFP units: None Reference    
                  1-2 0.63 0.15 0.54 0.24 
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                   >2 2.26 0.04 3.48 0.03 
Platelet transfusion 1.67 0.045 2.71 0.01 
Platelet units –          None Reference    
                                  1-2 1.63 0.10 2.49 0.046 
                                  >3 1.75 0.13 3.15 0.03 
     
Post-operative laboratory variables     
Urine 11-dhTXB2  (ln pg/mg creatinine) 1.59 0.03 2.43 0.001 
Urine 11-dhTXB2 tertiles     
         < 487 pg/mg creatinine Reference    
         ≥487 to <891pg/mg creatinine 1.25 0.54 2.55 0.13 
         ≥ 891 pg/mg creatinine 2.11 0.06 4.46 0.01 
     
6-month follow-up variables     
Medications:     
     Non-aspirin antiplatelet 1.85 0.10 1.60 0.39 
     Aspirin <325 mg daily 0.94 0.88 0.89 0.85 
     Oral anticoagulation 2.16 0.11 4.02 0.01 
     Beta-blocker 0.82 0.60 0.42 0.06 
     ACE Inhibitor/ARB 1.04 0.88 1.25 0.60 
     Lipid-lowering agent 0.59 0.16 0.33 0.01 
     Diuretic 1.21 0.54 1.58 0.26 
      Insulin 2.67 0.002 1.73 0.32 
      Insulin sensitizer 1.29 0.43 1.23 0.66 
      Insulin secretagogue 1.50 0.19 1.86 0.16 
eGFR (mL/min/1.73m2) 1.0 0.59 0.98 0.016 
LVEF at 6 Months     
     >50% Reference  Reference  
     30-50% 2.88 <0.001 4.55 <0.001 
     ≤30% 5.66 0.001 9.58 <0.001 
Graft occlusion     
     None Reference  Reference  
     1 0.81 0.54 0.50 0.17 
     2+ 1.88 0.06 0.48 0.34 
Percent of grafts occluded 1.0 0.03 1.0 0.69 
LIMA graft occlusion 3.26 0.001 0.90 0.89 
SVG occlusion     
    None Reference  Reference  
    1 0.89 0.73 0.61 0.33 
    2+ 1.44 0.35 0.38 0.34 
Laboratory variables:     
Leukocyte count     
                             4.5-11x103/mm3 Reference  Reference  
                             ≤4.5x103/mm3 1.02 0.96 1.67 0.36 
                             ≥11x103/mm3 4.16 0.02 4.73 0.04 
Hematocrit (%) 0.89 0.005 0.85 0.003 
Red cell distribution width (≤14.5 vs >14.5%) 1.44 0.18 1.46 0.35 
Platelet count (<150 vs. ≥150 x103/mm3) 1.44 0.32 6.47 0.07 
Reticulocyte (ln %) 1.89 0.27 0.34 0.09 
Blood Group: O vs. other 1.23 0.46 1.36 0.44 
Rh factor (positive vs. negative) 1.64 0.35 1.64 0.50 
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C-Reactive Protein (<5 vs. ≥5 mg/l-1) 1.87 0.03 2.33 0.04 
Fibrinogen (<390 vs. ≥390 mg/dL) 1.86 0.03 1.86 0.15 
vonWillebrand factor (>150 vs. ≤150%) 1.50 0.17 1.52 0.34 
eGFR (ml/min/1.73m2) 1.0 0.59 0.98 0.016 
Urine 8-iso Prostaglandin F2α (ln pg/mg creatinine) 1.53 0.02 1.52 0.13 
Urine 8-iso Prostaglandin F2α  
(≥1620 vs. <1620 pg/mg creatinine) 
1.96 0.03 1.68 0.24 
Urine TXB2  (ln pg/mg creatinine) 1.97 0.004 2.94 <0.001 
Urine TXB2  (>450 vs. ≤450 pg/mg creatinine) 2.15 0.006 3.33 0.003 
Oxidized LDL (<2.8 vs. ≥2.8 U/mL) 0.90 0.74 0.69 0.44 
Oxidized LDL        
                         <1.32 U/mL Reference  Reference  
                           1.32 to 5.04 U/mL 1.37 0.41 1.42 0.50 
                          >5.04 U/mL 0.91 0.81 0.63 0.47 
Cotinine  (≤10 vs. >10 ng/mL) 2.89 0.004 2.0 0.22 
Impedance platelet aggregometry (ohms)     
       ADP (20μM) 0.99 0.80 0.99 0.83 
       ADP (10μM) 0.98 0.53 0.95 0.19 
       ADP (5μM) 1.0 0.95 0.98 0.51 
       Collagen (1 µg.ml-1) 1.0 0.94 0.96 0.24 
       Epinephrine (50 µM) 1.0 0.51 0.99 0.77 
PFA-100 Collagen-ADP (Closure Time in sec-1) 1.0 0.63 1.0 0.18 
PFA-100 Collagen-ADP (Closure Time ≤88 sec vs. 
>88 sec) 
0.87 0.59 1.41 0.40 
PFA-100 Collagen-Epinephrine (Closure Time in 
sec-1) 
1.0 0.41 1.0 0.62 
Abbreviations: PCI= percutaneous coronary intervention; LVEF= left ventricular ejection fraction; 
SVG= saphenous vein graft; CABG= coronary artery bypass graft; RBS= red blood cell; FFP= fresh-
frozen plasma; ACE= angiotensin converting enzyme; ARB= angiotensin receptor blocker; LIMA= left 
internal mammary; 11-dhTXB2= 11-dehydro thromboxane B2; LDL= low density lipoprotein; eGFR= 
estimated glomerular filtration rate; ADP= adenosine diphosphate; PFA-100= Platelet Function 
Analyzer-100 
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Table S3. Univariate analyses of the association of urine 11-dhTXB2 with the individual components of the 5-year composite 
endpoint.  
Time of measure 3 Days (n=198) 
 
6 Months (n=288) 
 11-dhTXB2 (ln 
pg/mg creatinine) 
11-dhTXB2 (≤ 891 vs. > 
891 pg/mg creatinine) 
11-dhTXB2 (ln 
pg/mg creatinine) 
11-dhTXB2 (≤ 450 vs. > 
850 pg/mg creatinine) 
Outcome HR P-
value 
HR P-value Event Rate  HR P-value HR P-value Event Rate 
Death 2.43 0.001 2.66 0.017 12/146 vs. 
11/52 
2.94 0.001 3.3 0.003 12/213 vs. 
13/75 
MI 2.68 0.11 5.82 0.044 2/146 vs. 
4/52 
2.30 0.23 2.28 0.28 4/213 vs. 
3/75 
Revascularization 0.65 0.16 0.58 0.39 14/146 vs. 
3/52 
0395 0.83 1.06 0.90 17/213 vs. 
6/75 
Stroke 2.99 0.035 3.01 0.26 2/146 vs. 
2/52 
2.77 0.027 3.26 0.092 4/213 vs. 
4/75 
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Table S4. Multivariable Cox proportional hazard models for 6-month composite outcome. 
Variable Adj HR CI P-value 
Atrial fibrillation 5.73 1.62-20.24 0.007 
Number of SVG: 1 Reference   
                            2 0.22 0.07-0.68 0.008 
                            ≥3 0.76 0.19-2.98 0.69 
FFP units: None Reference   
                  1-2 5.40 0.68-42.9 0.11 
                   >2 14.62 1.62-132.2 0.017 
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